Drugs / CS20AT04
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03174587 | May 2017 → Mar 2019 | lupus nephritis | Corestemchemon, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04835883 | Sep 2019 → Nov 2021 | systemic lupus erythematosus | Hanyang University Seoul Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CS20AT04 | “Test group : CS20AT04 (allogenic bone marrow derived mesenchymal stem cells.)” NCT03174587 ↗ |
| Modality | Cell therapy | “allogenic bone marrow derived mesenchymal stem cells(CS20AT04)” NCT03174587 ↗ |
| Route | Intravenous | “The single injection of CS20AT04 Inj. in the peripheral veins.(IV)” NCT03174587 ↗ |